Table 2 Baseline characteristics of children receiving standard and revised dosage of anti-tubercular therapy
From: Pharmacokinetics of isoniazid, rifampicin, pyrazinamide and ethambutol in Indian children
Characteristics | Standard dosage, n = 64 | Revised dosage, n = 63 | ||
|---|---|---|---|---|
|  | Without severe malnutrition, n = 32 | With severe malnutrition, n = 32 | Without severe malnutrition, n = 37 | With severe malnutrition, n = 26 |
Age, mean (SD), months | 97.2 (43.9) | 105.9 (43.1) | 126.5 (28.4) | 91.3 (38.6) |
No of children, n (%) | Â | Â | Â | Â |
<2Â years of age | 1 (3.1) | 0 | 1 (2.7) | 1 (3.8) |
2-5 years | 6 (18.8) | 1 (3.1) | 9 (24.3) | 2 (7.7) |
>5Â years | 25 (78.1) | 31 (96.9) | 27 (73) | 23 (88.5) |
Boys, n (%) | 15 (46.9) | 15 (46.9) | 20 (54.1) | 16 (61.5) |
Received BCG, n (%) | 27 (84.4) | 21 (65.6) | 24 (77.4) | 20 (86.9) |
Weight for age z score, median (IQR) | −1.5 (−2.1, -0.7) | −2.7 (−3.2, -1.8) | −1.3 (−1.7, -0.4) | −1.9 (−2.4, -1.4) |
Height for age z score, median (IQR) | −1.4 (−2.03, 0) | −2.5 (−4.2, -1.6) | −1.1 (−1.9, -0.1) | −1.3 (−2.1, -0.7) |
Weight for height z score, median (IQR) | −1.1 (−1.9, -0.7) | −1.5 (−1.9, -1.03) | −0.6 (−1.1, -0.2) | −1.9 (−2.2, -1.3) |
BMI z score, median (IQR) | −0.8 (−1.4, -0.2) | −1.7 (−2.5, −0.6) | −0.7 (−1.2, −0.4) | −2.1 (−2.8, -1.8) |
AFB/MGIT positive, n (%) | 5 (15.6) | 9 (28.1) | 6 (16.2) | 7 (26.9) |
Diagnosis, n (%) | Â | Â | Â | Â |
Progressive pulmonary disease | 18 (56.2) | 18 (56.2) | 11(29.7) | 16 (61.5) |
Pleural effusion | 4 (12.5) | 4 (12.5) | 2 (5.4) | 0 |
Disseminated | 10 (31.3) | 10 (31.3) | 3 (8.1) | 0 |
Osteoarticular | 0 | 0 | 8 (21.6) | 3(11.5) |
Peripheral lymphadenopathy | 0 | 0 | 13 (35.2) | 7 (27) |